Grundlagen und Ergebnisse der antimykotischen Chemotherapie mit 5-Fluorocytosin (Part 1 of 2)
- 1 January 1976
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 22 (1) , 103-123
- https://doi.org/10.1159/000221961
Abstract
The current status of the oral antimycotic agent, 5-fluorocytosine (5-FC), is reviewed on the basis of extensive experience reported in literature from many parts of the world. Special attention is paid to basic experimental and pharmacological features such as spectrum of activity in vitro and in vivo, fungistatic and fungicidal properties, mechanism of action, primary and secondary resistance, sensitivity testing, assay in body fluids, pharmacokinetics and tolerance. Dosage of the drug, depending on kidney function, and also the advantages and problems of combined chemotherapy with 5-FC and amphotericin B, are discussed in detail.Keywords
This publication has 9 references indexed in Scilit:
- Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and ClearanceAnnals of Internal Medicine, 1974
- Prognostic Factors in Cryptococcal MeningitisAnnals of Internal Medicine, 1974
- Candida Endophthalmitis Complicating CandidemiaAnnals of Internal Medicine, 1973
- Candida albicans Arthritis Treated with FlucytosineAnnals of Internal Medicine, 1973
- 5-Fluorocytosine TherapyAnnals of Internal Medicine, 1972
- 5-Fluorocytosine in the Treatment of Mycotic InfectionsAnnals of Internal Medicine, 1972
- 5-Fluorocytosine: An Oral Antifungal CompoundAnnals of Internal Medicine, 1972
- 5-Fluorocytosine in the Treatment of Cryptococcal and Candida MycosesAnnals of Internal Medicine, 1971
- Amphotericin B in Cryptococcal MeningitisAnnals of Internal Medicine, 1969